Panel discussion

The Jackson Laboratory

Date:April 22, 2024

Panel title

Drug Discovery for Rare Diseases: from Genes to Treatments

Panel summary

Five experts in preclinical rare disease research will discuss the impact of recent technological and scientific advancements on rare disease drug development. The panelists come from diverse backgrounds, including academic research, preclinical, and clinical development, and each of them will offer a unique perspective on a range of arguments, from disease modeling to regulatory requirements.

Speaker information


Alexandre Reymond, Ph.D. , Professor, Center for Integrative Genomics of the University of Lausanne


Laurent Bogdanik, Ph.D., MBA, Associate Director, Preclinical Services – Neurology and Gene Therapy
Manolo Bellotto, Ph.D., Chief Strategy Officer and General Manager, Gain Therapeutics
Harald Petry, Ph.D., CEO, Avrion Therapeutics
Djordje Filipovic, Ph.D., CEO, AB2 Bio Ltd.

Company profile

The Jackson Laboratory (JAX) is a non-profit research institute founded in 1929 to further the study of genetics and cancer. Throughout the years, the Jackson Laboratory has remained dedicated to expanding and sharing biomedical knowledge and aims to increase access to its science by providing translational models and preclinical services to drug developers.

Follow us